Foundation provides $1.5 million grant for ongoing PTSD, TBI treatment study

The Engelstad Foundation has provided a $1.5 million grant to Wave Neuroscience in support of the company’s ongoing phase 2 clinical trial to develop and validate innovative treatments for post-traumatic stress disorder and traumatic brain injury.

According to a release from the foundation’s, the study, conducted with Texas A&M University Health Science Center Institute of Biosciences and Technology, will evaluate the efficacy of Wave’s 7 Magnetic EEG-guided Resonance Therapy.

“Wave Neuroscience is on the frontlines with such a compassionate mission — to help improve the lives of those with PTSD and [traumatic brain injury],” Engelstad Foundation trustee Kris Engelstad, stated in the release. “We see this grant as not only an investment in Wave Neuroscience’s incredible treatment efforts and research, but the ultimate wellbeing of so many out there.”

According to statistics cited in the release from the National Center for PTSD and the CDC, approximately 13 million U.S. residents suffered from PTSD in 2020, with roughly 214,110 TBI-related hospitalizations recorded that same year.

“We are deeply grateful for the Engelstad Foundation's incredible generosity and support,” Wave CEO Fred Walke said in the release. “Their donation will significantly accelerate our efforts to bring new, effective treatments to individuals suffering from PTSD and TBI. We look forward to the potential impact this will have on mental health care.”